SUPN Gets Attention, AST For The Long Haul, OCUL To File NDA In Q2, ZGNX Slumps

Akebia Therapeutics Inc. (AKBA: Quote) has completed enrollment in the third and final cohort of its phase 2 clinical study evaluating AKB-6548, a once-daily oral therapy, in patients with anemia related to chronic kidney disease who are undergoing dialysis.

The company expects to report top-line results from the study in the third quarter of 2015.

AKBA closed Tuesday's trading at $11.43, down 0.17%.

Alcobra Ltd.'s (ADHD: Quote) phase II safety and tolerability study of a single administration of MDX in adolescent patients with ADHD has achieved its primary endpoint. In the study, MDX showed good tolerability and no safety concerns were identified, according to the company.

A separate study evaluating MDX in adolescents and adults with Fragile X Syndrome is currently underway, and results are expected to be reported by the end of 2Q15.

ADHD closed Tuesday's trading at $7.11, up 0.99%.

Asterias Biotherapeutics Inc. (AST: Quote) is a stock worth putting on your radar as the company expects multiple, meaningful clinical milestones over the next 24 months.

The company recently initiated patient enrollment in a dose-escalation phase 1/2a clinical trial of AST-OPC1 in patients with complete cervical spinal cord injury (SCI). The trial is an open-label, single-arm study testing three escalating doses of AST-OPC1 in patients with sub-acute, C-5 to C-7, neurologically complete cervical SCI. The dose escalation will start with three patients being dosed 2 million cells and escalate into two five-patient cohorts at 10 million and 20 million cells, respectively.

The company expects the safety data readout from the initial low-dose, 2 million cell cohort and initiation of the 10 million cell cohort in the second quarter of 2015.

The company said that its AST-VAC2 allogeneic dendritic cell-based cancer vaccine will be investigated for initial measures of clinical activity and safety in a phase 1/2a trial in non-small cell lung cancer, and expects to complete and transfer the manufacturing process for AST-VAC2 to its development partner in the second quarter of this year.

Read more:
SUPN Gets Attention, AST For The Long Haul, OCUL To File NDA In Q2, ZGNX Slumps